Sware
Assembly Line
Sware Raises $6M to Accelerate Life Sciences Innovation by Automating FDA-Mandated Software Validation
Sware, provider of the most complete software validation solution for innovative life sciences companies, announced that it raised $6 million in Series B funding, bringing its total raised since inception to $26 million. The round was led by First Analysis, which joins a syndicate of existing investors that includes LRVHealth, New Stack Ventures and Insight Partners. The funding will be used to bolster research and development of Sware’s computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company’s sales team so it can bring the platform to more organizations struggling with validation debt, the unpaid cost of release, testing, GxP, and business requirements. As a result of the funding, Matt Nicklin, managing director at First Analysis, will join the company’s board of directors.